GSK buys liver drug from Boston Pharmaceuticals for up to $2 billion The Boston Globe Nawigacja wpisu GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) – Business Wire Medical students provide free health screenings at community clinic – VCU News
